Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Janux Therapeutics Inc (JANX)
NASDAQ:JANX
Janux Therapeutics Inc (JANX) Stock Price & Analysis
188 Followers
JANX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.65 - $65.60
Previous Close$47.1
Volume698.03K
Average Volume (3M)1.15M
Market Cap
$2.44B
Enterprise Value$2.12B
Total Cash (Recent Filing)$344.03M
Total Debt (Recent Filing)$24.54M
Price to Earnings (P/E)-38.5
Beta1.92
Next Earnings
Aug 06, 2024EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding51,850,667
10 Day Avg. Volume928,652
30 Day Avg. Volume1,152,418
Standard Deviation0.84
R-Squared0.06
Alpha0.12
Financial Highlights & Ratios
Price to Book (P/B)7.09
Price to Sales (P/S)283.58
Price to Cash Flow (P/CF)-61.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue351.73
Enterprise Value/Gross Profit246.48
Enterprise Value/Ebitda-45.66
Forecast
1Y Price Target
$72.17Price Target Upside53.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Janux Therapeutics Inc News
Bulls Say, Bears Say
Bulls Say
Analyst ExpectationsAnalysts have raised the 12-month price target for the stock based on a risk-adjusted net present value analysis of projected future revenues.
Clinical Trial ResultsInitial data from the Phase 1 study showed efficacy and safety potential of JANX-007 as a monotherapy in mCRPC patients.
Mergers And Acquisitions PotentialInvestor interest increased following Bloomberg alert on potential for M&A, pushing the stock up.
Bears Say
Drug EfficacyData are not mature enough to determine the durability of response.
Financial PerformanceJANX reported a Q4 net loss of $11.8MM.
Market ApprovalWe still don't know whether biomarker based selection would be necessary to identify the target patient population.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
JANX FAQ
What was Janux Therapeutics Inc’s price range in the past 12 months?
Janux Therapeutics Inc lowest stock price was $5.65 and its highest was $65.60 in the past 12 months.
What is Janux Therapeutics Inc’s market cap?
Currently, no data Available
When is Janux Therapeutics Inc’s upcoming earnings report date?
Janux Therapeutics Inc’s upcoming earnings report date is Aug 06, 2024 which is in 78 days.
How were Janux Therapeutics Inc’s earnings last quarter?
Janux Therapeutics Inc released its earnings results on May 07, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.331 by $0.031.
Is Janux Therapeutics Inc overvalued?
According to Wall Street analysts Janux Therapeutics Inc’s price is currently Undervalued.
Does Janux Therapeutics Inc pay dividends?
Janux Therapeutics Inc does not currently pay dividends.
What is Janux Therapeutics Inc’s EPS estimate?
Janux Therapeutics Inc’s EPS estimate is -$0.31.
How many shares outstanding does Janux Therapeutics Inc have?
Janux Therapeutics Inc has 51,850,666 shares outstanding.
What happened to Janux Therapeutics Inc’s price movement after its last earnings report?
Janux Therapeutics Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.331. Following the earnings report the stock price went down -9.967%.
Which hedge fund is a major shareholder of Janux Therapeutics Inc?
Among the largest hedge funds holding Janux Therapeutics Inc’s share is RA Capital Management. It holds Janux Therapeutics Inc’s shares valued at 98M.
---
Janux Therapeutics Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$72.17 (53.23% Upside)
$72.17 (53.23% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 85.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
292.50%
12-Months-Change
Fundamentals
Return on Equity
-11.50%
Trailing 12-Months
Asset Growth
95.20%
Trailing 12-Months
Company Description
Janux Therapeutics Inc
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
---
JANX Stock 12 Month Forecast
Average Price Target
$72.17
▲(53.23% Upside)
Technical Analysis
Best Analysts Covering JANX
1 Year
1 Year Success Rate
7/14 ratings generated profit
1 Year Average Return
+101.74%
reiterated a buy rating 7 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +101.74% per trade.
---